Scalper1 News
Biotech Kite Pharma (KITE) got an upgrade to outperform from FBR Tuesday on a bullish outlook for its experimental cancer therapies. “Kite made tremendous progress in 2015, and 2016 looks to be no different, with a slew of potential meaningful milestones,” wrote analyst Ed White in his research note. He pointed to last week’s update of Kite’s phase-two trial of its chimeric antigen receptor (CAR) T-cell therapy KTE-C19 in blood cancer, in which Scalper1 News
Scalper1 News